Meta-analysis finds bright light therapy boosts remission and response in nonseasonal depression, offering a low-cost add-on to standard care.
|Slideshows|September 18, 2018
Depression Research: Vagus Nerve Stimulation, Omega-3 Supplementation, Adolescent Psychiatry
Author(s)Mark L. Fuerst
New studies in major depression find VNS improves the quality of life of patients with treatment-resistant depression and two other findings.
Advertisement
Advertisement
Related to this article
Mixed-feature depression can signal bipolar risk; spot red flags and consider lurasidone or lumateperone before standard antidepressants.
Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
2
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
3
FDA Shelves Fast-Track Drug Review Initiative
4
Ahead of the FDA Action Date: A Timeline of Igalmi for Agitation in Bipolar Disorder and Schizophrenia
5